RU2018141200A - Способы и композиции для лечения опухолей - Google Patents
Способы и композиции для лечения опухолей Download PDFInfo
- Publication number
- RU2018141200A RU2018141200A RU2018141200A RU2018141200A RU2018141200A RU 2018141200 A RU2018141200 A RU 2018141200A RU 2018141200 A RU2018141200 A RU 2018141200A RU 2018141200 A RU2018141200 A RU 2018141200A RU 2018141200 A RU2018141200 A RU 2018141200A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- pluripotent
- population
- paragraphs
- inactivated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 5
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 210000004027 cell Anatomy 0.000 claims 26
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical group CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 4
- 230000000644 propagated effect Effects 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 239000003471 mutagenic agent Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims 1
- 229950008805 abexinostat Drugs 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
- 229960003094 belinostat Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229950009221 chidamide Drugs 0.000 claims 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- 229950005837 entinostat Drugs 0.000 claims 1
- 229950010415 givinostat Drugs 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 231100000636 lethal dose Toxicity 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- WXHHICFWKXDFOW-BJMVGYQFSA-N n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide Chemical compound NC1=CC=C(F)C=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 WXHHICFWKXDFOW-BJMVGYQFSA-N 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (27)
1. Применение комбинации (I) ингибитора гистондезацетилазы (HDACi) и (II) композиции вакцины, содержащей популяцию плюрипотентных клеток, которые были инактивированы для получения лекарственного средства для одновременного, раздельного или последовательного введения для терапевтического или профилактического лечения рака у субъекта.
2. Применение по п. 1, где субъект представляет собой человека.
3. Применение по п. 1, дополнительно включающее HDACi для введения через некоторое время после введения композиции вакцины.
4. Применение по любому из пп. 1-3, где популяция плюрипотентных клеток была получена путем:
a) размножения плюрипотентных клеток при наличии таких условий, которые поддерживают плюрипотентную способность клеток, в присутствии агента, который индуцирует презентацию антигенов MHC-I (Главным комплексом гистосовместимости 1-го класса) у указанной популяции во время стадии размножения;
b) подвергания размноженных клеток воздействию инактивирующего агента, который инактивирует клетки, при этом сохраняя целостность клеточной оболочки;
c) восстановления и консервации размноженных инактивированных клеток.
5. Применение по любому из пп. 1-4, где клетки популяции экспрессируют представляющий интерес антиген, также экспрессируемый раковыми клетками субъекта, и, в частности, неоантиген.
6. Способ получения популяции плюрипотентных клеток, которые были инактивированы, включающий стадии:
I) размножения плюрипотентных клеток при наличии таких условий, которые поддерживают плюрипотентную способность клеток, в присутствии агента, который индуцирует презентацию антигенов MHC-I у указанной популяции во время стадии размножения;
II) подвергания размноженных клеток воздействию инактивирующего агента, который инактивирует клетки, при этом сохраняя целостность клеточной оболочки;
III) восстановления и консервации размноженных инактивированных клеток.
7. Способ по п. 6, где популяция плюрипотентных клеток выбрана из группы, состоящей из эмбриональных стволовых клеток человека, индуцированных плюрипотентных стволовых клеток (iPS), аллогенных, ксеногенных, аутологичных и сингенных стволовых клеток.
8. Способ по п. 6 или 7, где плюрипотентные клетки подвергают воздействию мутагенного агента во время размножения, с тем чтобы индуцировать мутагенез генов в клетках указанной популяции.
9. Способ по любому из пп. 6-8, где агент, который индуцирует презентацию антигенов MHC-I и усиливает плюрипотентный ген, представляет собой ингибитор гистондезацетилазы (HDACi).
10. Способ по п. 9, где ингибитор гистондезацетилазы выбран из группы, состоящей из вальпроевой кислоты (VPA), вориностата, панобиностата, гивиностата, белиностата, энтиностата, моцетиностата, практиностата, чидамида, квизиностата и абексиностата.
11. Способ по любому из пп. 6-10, где на стадии I) присутствует ингибитор ДНК-метилтрансферазы, в частности 5-азацитидин.
12. Способ по любому из пп. 6-11, где клетки инактивируют воздействием летальной дозы облучения.
13. Композиция противораковой вакцины вакцины, содержащая:
a) популяцию инактивированных плюрипотентных клеток и
b) ингибитор гистондезацетилазы.
14. Композиция вакцины по п. 13, где плюрипотентные клетки содержат мутагенезированные плюрипотентные клетки.
15. Применение комбинированного препарата из I) популяции инактивированных плюрипотентных клеток и II) соединения, которое активирует экспрессию МНС и/или иммунный ответ для получения лекарственного средства для одновременного, отдельного или последовательного введения для лечения субъекта, страдающего от рака.
16. Применение по п. 15, где популяция плюрипотентных клеток выбрана из группы, состоящей из эмбриональных стволовых клеток человека, индуцированных плюрипотентных стволовых клеток (iPS), аллогенных, ксеногенных, аутологичных или сингенных стволовых клеток.
17. Применение по п. 15 или 16, где плюрипотентные клетки генетически модифицированы для сверхэкспрессии соединений, которые стимулируют экспрессию МНС и/или иммунный ответ.
18. Применение по любому из пп. 15-17, где плюрипотентные клетки были обработаны мутагенным агентом.
19. Применение по любому из пп. 15-18, дополнительно включающее введение ингибитора иммунных контрольных точек субъекту.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305607 | 2016-05-25 | ||
EP16305607.0 | 2016-05-25 | ||
PCT/EP2017/062604 WO2017202949A1 (en) | 2016-05-25 | 2017-05-24 | Methods and compositions for treating cancers |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018141200A true RU2018141200A (ru) | 2020-06-25 |
RU2018141200A3 RU2018141200A3 (ru) | 2020-07-29 |
RU2741786C2 RU2741786C2 (ru) | 2021-01-28 |
Family
ID=56131478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018141200A RU2741786C2 (ru) | 2016-05-25 | 2017-05-24 | Способы и композиции для лечения опухолей |
Country Status (11)
Country | Link |
---|---|
US (2) | US11458194B2 (ru) |
EP (1) | EP3463433A1 (ru) |
JP (2) | JP7563872B2 (ru) |
KR (3) | KR20240103039A (ru) |
CN (2) | CN116376812A (ru) |
AU (2) | AU2017270234B2 (ru) |
BR (1) | BR112018074192A8 (ru) |
CA (1) | CA3025057A1 (ru) |
IL (2) | IL263224B2 (ru) |
RU (1) | RU2741786C2 (ru) |
WO (1) | WO2017202949A1 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CN111670043A (zh) | 2017-11-24 | 2020-09-15 | 国家医疗保健研究所 | 治疗癌症的方法和组合物 |
BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
WO2019136038A1 (en) | 2018-01-02 | 2019-07-11 | Khloris Biosciences, Inc. | Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer |
US20200368280A1 (en) * | 2018-01-12 | 2020-11-26 | Viracta Therapeutics, Inc. | Epigenetic modifiers for use in cellular immunotherapy |
CN112703011A (zh) * | 2018-08-06 | 2021-04-23 | 国家医疗保健研究所 | 用于治疗癌症的方法和组合物 |
US20220154219A1 (en) * | 2019-03-22 | 2022-05-19 | The Johns Hopkins University | Gene delivery particles to induce tumor-derived antigen presenting cells |
US20220235348A1 (en) * | 2019-05-15 | 2022-07-28 | Board Of Regents, The University Of Texas System | Crispr methods for treating cancers |
JP7352937B2 (ja) * | 2019-07-19 | 2023-09-29 | 公立大学法人福島県立医科大学 | 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット |
CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
CA3178656A1 (en) * | 2020-05-12 | 2021-11-18 | Rush Medical University Center | Compositions and methods for treating cancer |
CN112603995B (zh) * | 2020-12-30 | 2022-03-18 | 四川省肿瘤医院 | 靶向CAFs的肿瘤细胞疫苗、其制备方法及其应用 |
BR112023019492A2 (pt) * | 2021-03-31 | 2023-10-31 | Celleron Therapeutics Ltd | Composto ou um sal ou solvato farmaceuticamente aceitável do mesmo, métodos para tratar ou prevenir uma doença, distúrbio ou condição, para potencializar uma resposta imunológica, para potencializar o efeito de uma vacina, para sensibilizar o sistema imunológico de um indivíduo, para potencializar a resposta imunológica a uma vacina em um indivíduo e para prevenir ou tratar uma doença, distúrbio ou condição, usos do composto ou um sal farmaceuticamente aceitável do mesmo e de uma combinação, combinação, produto farmacêutico, e, composição farmacêutica |
EP4316494A1 (en) * | 2021-04-05 | 2024-02-07 | Pinotbio, Inc. | Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax |
WO2023159124A2 (en) * | 2022-02-17 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Methods for overcoming tazemetostat-resistance in cancer patients |
WO2024178965A1 (en) * | 2023-02-27 | 2024-09-06 | Wuhan University | Modulation of pd-1 signaling for treatment of diseases |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
US4806476A (en) | 1983-09-08 | 1989-02-21 | Lovelace Medical Foundation | Efficient cell fusion process |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
US5166065A (en) | 1988-08-04 | 1992-11-24 | Amrad Corporation Limited | In vitro propagation of embryonic stem cells |
US5240840A (en) | 1991-04-05 | 1993-08-31 | Regents Of The University Of Michigan | Dna superfragment cloning |
JP3314241B2 (ja) | 1992-04-06 | 2002-08-12 | ヤマハ発動機株式会社 | 自動二輪車用エンジンの排気浄化装置 |
US5690926A (en) | 1992-10-08 | 1997-11-25 | Vanderbilt University | Pluripotential embryonic cells and methods of making same |
US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
ATE361759T1 (de) | 1993-07-15 | 2007-06-15 | Cancer Res Campaign Tech | Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
CN1145614C (zh) | 1996-04-12 | 2004-04-14 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂,其制药用途及药物组合物 |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US6331406B1 (en) | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
AU1197699A (en) | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
US6835867B1 (en) | 1998-06-24 | 2004-12-28 | Richard P. Woychik | Allelic series of genomic modifications in cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
CA2376957A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
EP1194152A4 (en) | 1999-06-30 | 2002-11-06 | Merck & Co Inc | SIN KINASE INHIBITOR COMPOUNDS |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
DK1212422T3 (da) | 1999-08-24 | 2007-07-02 | Medarex Inc | Humane CTLA-4-antistoffer og anvendelserne deraf |
HUP0202682A3 (en) | 1999-09-10 | 2003-03-28 | Merck & Co Inc | Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2001028993A2 (en) | 1999-10-19 | 2001-04-26 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
ATE286045T1 (de) | 1999-10-19 | 2005-01-15 | Merck & Co Inc | Tyrosin kinaseinhibitoren |
US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
NL1017973C2 (nl) | 2000-05-10 | 2002-11-08 | Tristem Trading Cyprus Ltd | Inrichting. |
AU785428B2 (en) | 2000-08-30 | 2007-05-17 | Maria Biotech Co., Ltd | Human embryonic stem cells derived from frozen-thawed embryo |
EP1403366B1 (en) | 2001-05-31 | 2015-05-27 | Shinya Yamanaka | Genes with es cell-specific expression |
AU2002346053B2 (en) | 2001-06-22 | 2008-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003011836A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6927293B2 (en) | 2001-08-30 | 2005-08-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP4488740B2 (ja) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫細胞活性化を調節する作用剤およびその使用方法 |
CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
JP4976852B2 (ja) | 2003-11-10 | 2012-07-18 | ザ スクリプス リサーチ インスティチュート | 細胞脱分化を誘導するための組成物および方法 |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
EP1907424B1 (en) | 2005-07-01 | 2015-07-29 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
JP2009544362A (ja) | 2006-07-20 | 2009-12-17 | バート リチャード | 損傷を受けた組織の修復のための有糸分裂的に不活性化された幹細胞の使用方法 |
US20100093862A1 (en) | 2006-12-06 | 2010-04-15 | Sapporo Medical Univeristy And Japan Science And Technology Agency | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors. |
KR20100054780A (ko) | 2007-06-18 | 2010-05-25 | 엔.브이.오가논 | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
EP2268809B1 (en) | 2008-05-02 | 2019-02-06 | Kyoto University | Method of nuclear reprogramming |
CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
PT4209510T (pt) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t |
WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9637732B2 (en) | 2010-11-04 | 2017-05-02 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
US9534206B2 (en) * | 2010-12-16 | 2017-01-03 | General Electric Company | Cell carrier, associated methods for making cell carrier and culturing cells using the same |
US20130136722A1 (en) | 2011-11-11 | 2013-05-30 | The Board Of Trustees Of The University Of Illinois | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
-
2017
- 2017-05-24 BR BR112018074192A patent/BR112018074192A8/pt not_active Application Discontinuation
- 2017-05-24 AU AU2017270234A patent/AU2017270234B2/en active Active
- 2017-05-24 IL IL263224A patent/IL263224B2/en unknown
- 2017-05-24 CN CN202211701185.XA patent/CN116376812A/zh active Pending
- 2017-05-24 CN CN201780045481.XA patent/CN109689089A/zh active Pending
- 2017-05-24 CA CA3025057A patent/CA3025057A1/en active Pending
- 2017-05-24 EP EP17726274.8A patent/EP3463433A1/en active Pending
- 2017-05-24 KR KR1020247020115A patent/KR20240103039A/ko active Search and Examination
- 2017-05-24 KR KR1020187037459A patent/KR20190032295A/ko not_active IP Right Cessation
- 2017-05-24 JP JP2018561512A patent/JP7563872B2/ja active Active
- 2017-05-24 IL IL305882A patent/IL305882A/en unknown
- 2017-05-24 RU RU2018141200A patent/RU2741786C2/ru active
- 2017-05-24 US US16/303,705 patent/US11458194B2/en active Active
- 2017-05-24 WO PCT/EP2017/062604 patent/WO2017202949A1/en unknown
- 2017-05-24 KR KR1020227044304A patent/KR102677451B1/ko active IP Right Grant
-
2022
- 2022-07-07 JP JP2022110028A patent/JP2022133444A/ja active Pending
- 2022-07-28 US US17/815,586 patent/US20220370582A1/en active Pending
-
2024
- 2024-01-30 AU AU2024200549A patent/AU2024200549A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019516754A (ja) | 2019-06-20 |
KR20190032295A (ko) | 2019-03-27 |
US20220370582A1 (en) | 2022-11-24 |
KR20240103039A (ko) | 2024-07-03 |
US11458194B2 (en) | 2022-10-04 |
JP2022133444A (ja) | 2022-09-13 |
IL263224B1 (en) | 2023-11-01 |
JP7563872B2 (ja) | 2024-10-08 |
WO2017202949A1 (en) | 2017-11-30 |
BR112018074192A2 (pt) | 2019-08-13 |
IL263224A (en) | 2018-12-31 |
RU2018141200A3 (ru) | 2020-07-29 |
KR102677451B1 (ko) | 2024-06-24 |
AU2024200549A1 (en) | 2024-02-15 |
KR20230003387A (ko) | 2023-01-05 |
IL263224B2 (en) | 2024-03-01 |
IL305882A (en) | 2023-11-01 |
BR112018074192A8 (pt) | 2022-11-08 |
AU2017270234B2 (en) | 2023-11-23 |
RU2741786C2 (ru) | 2021-01-28 |
CN109689089A (zh) | 2019-04-26 |
US20210162031A1 (en) | 2021-06-03 |
AU2017270234A1 (en) | 2019-01-17 |
CN116376812A (zh) | 2023-07-04 |
CA3025057A1 (en) | 2017-11-30 |
EP3463433A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018141200A (ru) | Способы и композиции для лечения опухолей | |
JP2019516754A5 (ru) | ||
Gotwals et al. | Prospects for combining targeted and conventional cancer therapy with immunotherapy | |
Zhou et al. | Neutrophil–hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis | |
Mishra et al. | Identifying the therapeutic significance of mesenchymal stem cells | |
Conte et al. | HDAC inhibitors as epigenetic regulators for cancer immunotherapy | |
He et al. | Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model | |
Guillonneau et al. | Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity | |
Ben-Yedidia et al. | Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection | |
Wefers et al. | Immune curbing of cancer stem cells by CTLs directed to NANOG | |
JP2021504465A5 (ru) | ||
O’Donnell et al. | Salmonella as a model for non-cognate Th1 cell stimulation | |
Bhattacharyya et al. | Regulation of CD 4 T cells and their effects on immunopathological inflammation following viral infection | |
van Duijn et al. | CD39 identifies a microenvironment-specific anti-inflammatory CD8+ T-cell population in atherosclerotic lesions | |
RU2014117946A (ru) | Композиции и способы иммунизации с применением лигандов cd1d | |
Müller et al. | Modeling chronic graft-versus-host disease in MHC-matched mouse strains: genetics, graft composition, and tissue targets | |
Walker et al. | Preventing and curing citrulline‐induced autoimmune arthritis in a humanized mouse model using a Th2‐polarizing iNKT cell agonist | |
ES2860823T3 (es) | Prevención y tratamiento de afecciones inflamatorias | |
Orekhov et al. | Role of Mitochondria in the Chronification of Inflammation: Focus on Dysfunctional Mitophagy and Mitochondrial DNA Mutations | |
Hasegawa et al. | Liver injury after invariant NKT cell activation by free alpha-galactosylceramide and alpha-galactosylceramide-loaded dendritic cells | |
Mallone et al. | Of bugs and men: antigen-fortified Lactoccoccus lactis for type 1 diabetes immunotherapy. | |
Molnar et al. | 23.2. Adaptive immune response | |
Chakrabarti et al. | Regenerative Approach to the Treatment of COVID-19 Patients. | |
US8110193B2 (en) | Methods for conditioning a subject for hematopoietic cell transplantation | |
Papanastasatou et al. | Invariant Natural Killer T cells control positively and negatively the development of hepatocellular carcinoma |